← Eichor
Condition: Prostatic Neoplasms Castration Resistant Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Prostatic Neoplasms Castration Resistant

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Canc
Phase 3 · 136 location(s) · Janssen Research & Development, LLC · NCT07225946Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Particip
Phase 1/Phase 2 · 77 location(s) · Merck Sharp & Dohme LLC · NCT06353386A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 3 · 172 location(s) · Janssen Research & Development, LLC · NCT07164443Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib +
Phase N/A · 34 location(s) · AstraZeneca · NCT06380738A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 35 location(s) · AstraZeneca · NCT07590934A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Phase 1/Phase 2 · 81 location(s) · Novartis Pharmaceuticals · NCT04104776Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06567314A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Phase 1/Phase 2 · 4 location(s) · Institute of Cancer Research, United Kingdom · NCT07002320Castrate Resistant Prostate Cancer Enhertu Therapy
Phase 2 · 1 location(s) · Washington D.C. Veterans Affairs Medical Center · NCT06610825Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resista
Phase N/A · 1 location(s) · Yonsei University · NCT06236789Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177
Phase N/A · 1 location(s) · Hannah Schaefer · NCT06720532Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Pr
Phase 2 · 1 location(s) · Pengyuan Liu · NCT06249750ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Phase 3 · 32 location(s) · Karolinska Institutet · NCT03903835GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
Phase 1 · 1 location(s) · Virginia Commonwealth University · NCT06636123A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1 · 8 location(s) · Bristol-Myers Squibb · NCT06067841Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to C
Phase 3 · 174 location(s) · SWOG Cancer Research Network · NCT06470243A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Phase 2 · 50 location(s) · Astellas Pharma Global Development, Inc. · NCT07005154A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patient
Phase 1 · 1 location(s) · Xiaorong Sun · NCT07135102Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Phase N/A · 2 location(s) · Santa Chiara Hospital · NCT06783127Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Phase 1/Phase 2 · 1 location(s) · Charles Drew University of Medicine and Science · NCT06615752A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · 329 location(s) · Merck Sharp & Dohme LLC · NCT06136650Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT05116579Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detecte
Phase 3 · 4 location(s) · UNICANCER · NCT06276465Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT06305598Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response G
Phase 3 · 14 location(s) · Canadian Cancer Trials Group · NCT06439225Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06236139
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.